material information disclosure

Apollo Global Management faces class action lawsuit alleging leadership failed to disclose material communications with Jeffrey Epstein in the 2010s.

uniQure faces securities fraud lawsuit after FDA rejection of AMT-130 data triggers 49% stock plunge from $67.69 to $34.29 on November 3, 2025.

Law firm files class action against $ENPH for allegedly overstating inventory management and financial prospects during 2025.

uniQure's stock plummeted 49% after FDA rejected its AMT-130 drug candidate; securities fraud lawsuit filed for alleged failure to disclose approval risks during September-October 2025.

Law firm Kahn Swick & Foti files class action against $ENPH alleging financial misstatements; April 20, 2026 deadline for lead plaintiff applications.

Corcept Therapeutics faces securities class action after FDA rejected relacorilant, causing 50% stock collapse. Investors have until April 21 to file claims.

Enphase Energy faces securities class action over alleged disclosure failures regarding inventory management and tax credit impacts. Lead plaintiff deadline set for April 20, 2026.

uniQure faces securities lawsuit after FDA rejected AMT-130 drug candidate data adequacy. Stock plunged 49% following disclosure. Lead plaintiff deadline April 13, 2026.

Ultragenyx stock crashes 42% after disclosing failed Phase 3 trial for setrusumab; investors with losses exceeding $100,000 have until April 6, 2026 to file lead plaintiff applications in class action lawsuit.

Gartner faces securities fraud suit after 48% stock decline linked to reduced guidance. Investors can apply as lead plaintiffs through Kahn Swick & Foti, LLC.

Class action lawsuit filed against Corcept Therapeutics alleging securities fraud tied to FDA rejection of relacorilant, triggering 50% stock plunge.

Class action lawsuit filed against $ENPH alleges securities fraud over channel inventory management and Clean Energy Credit disclosure failures. Deadline for lead plaintiff claims: April 20, 2026.

Apollo Global Management faces a securities class action lawsuit alleging leadership concealed Epstein communications. Investors with losses exceeding $100,000 must apply for lead plaintiff status by May 1, 2026.

Enphase Energy shareholders must file lead plaintiff applications by April 20, 2026 in a class action alleging disclosure failures regarding inventory management and tax credit impacts.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant. Stock crashed 50% following misleading investor claims about approval prospects.

BellRing Brands faces securities fraud class action for failing to disclose inventory issues. Stock plummeted 52% after May and August 2025 negative announcements.

Trip.com faces securities fraud lawsuit after China's antitrust probe; stock plunged 19.4% with investors losing $12.90 per share initially.

Ultragenyx Pharmaceutical's stock plunged 42% after failing to disclose setrusumab Phase 3 trial failure, triggering securities litigation with April 6, 2026 lead plaintiff deadline.

uniQure faces securities lawsuit after FDA rejected AMT-130 approval pathway. Stock plummeted 49% following disclosure. Lead plaintiff deadline: April 13, 2026.

Apollo Global Management faces class action over alleged Epstein executive communications non-disclosure. Investors with $100,000+ losses must apply as lead plaintiffs by May 1, 2026.